Amendments to the Patented Medicines Price Review Board regulations came into force in July 2022, with an interim approach to price assessments in the absence of new guidelines to assist manufacturers in the prepare for the changes.

After delays to the release of new guidelines a policy roundtable has been announced inviting stakeholders to share views on key themes intended to assist with the drafting process.

This session will provide an overview of the latest developments to date on drug pricing in Canada and what manufacturers can expect moving into 2024.